BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cadus Corporation (KDUS) Reports First Quarter 2012 Results


5/15/2012 9:22:52 AM

NEW YORK, NY--(Marketwire - May 15, 2012) - Cadus Corporation (OTCBB: KDUS) announced today financial results for the first quarter ended March 31, 2012.

Revenues for the first quarter of 2012 were $0, compared to $0 for the same period in 2011. Net loss for the first quarter of 2012 increased to $155,485, compared to a net loss of $153,883 for the same period in 2011. The increase in net loss can be principally attributed to an increase in general and administrative expenses of $410, a decrease in interest income of $1,178 and a decrease in income from other ventures of $14. Basic net loss per share for the first quarter of 2012 was $0.01, compared to basic net loss per share for the first quarter of 2011 of $0.01.

As of March 31, 2012, Cadus had 13,144,040 shares outstanding.

This press release may contain forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's annual report on Form 10-K for the year ended December 31, 2011. These include risks and uncertainties relating to the company's ability to license its technologies to third parties, the company's ability to acquire and operate other companies, the company's capital needs and uncertainty of future funding, the company's history of operating losses, the unpredictability of patent protection and the risk of obsolescence of the company's technologies.

                                                                            
                                                                            
                              CADUS CORPORATION                             
                    Condensed Consolidated Balance Sheets                   
                                                                            
                                   ASSETS                                   
                                                                            
                                          March 31, 2012  December 31, 2011 
                                        ----------------- ----------------- 
                                           (Unaudited)        (Audited)     
Current assets:                                                             
                                                                            
  Cash and cash equivalents             $      23,333,079 $      23,376,400 
  Interest receivable                                 197               190 
  Prepaid and other current assets                 15,240             7,090 
                                        ----------------- ----------------- 
                                                                            
    Total current assets                       23,348,516        23,383,680 
                                                                            
Investment in other ventures                      194,032           194,025 
Patents, net                                      183,494           205,102 
                                        ----------------- ----------------- 
      Total assets                      $      23,726,042 $      23,782,807 
                                        ================= ================= 
                                                                            
                    LIABILITIES AND STOCKHOLDERS' EQUITY                    
                                                                            
Current liabilities:                                                        
  Accrued expenses and other current                                        
   liabilities                          $         106,554 $           7,834 
                                        ----------------- ----------------- 
    Total current liabilities                     106,554             7,834 
                                        ----------------- ----------------- 
                                                                            
Commitments                                                                 
                                                                            
Stockholders' equity:                                                       
                                                                            
  Common stock                                    132,857           132,857 
  Additional paid-in capital                   59,847,443        59,847,443 
  Accumulated deficit                         (36,060,737)      (35,905,252)
  Treasury stock - at cost                       (300,075)         (300,075)
                                        ----------------- ----------------- 
    Total stockholders' equity                 23,619,488        23,774,973 
                                        ----------------- ----------------- 
    Total liabilities and stockholders'                                     
     equity                             $      23,726,042 $      23,782,807 
                                        ================= ================= 
                                                                            
                                                                            
                              CADUS CORPORATION                             
               Condensed Consolidated Statements of Operations              
                                                                            
                                                   Three Months Ended       
                                                       March 31,            
                                            ------------------------------- 
                                                  2012            2011      
                                            --------------- --------------- 
                                              (Unaudited)     (Unaudited)   
License and maintenance fees                $           -0- $           -0- 
                                            --------------- --------------- 
    Total revenues                                      -0-             -0- 
                                            --------------- --------------- 
Costs and expenses:                                                         
  General and administrative expenses               134,538         134,128 
  Amortization of patent costs                       21,608          21,608 
  (Income) from equity in other ventures                 (7)            (21)
                                            --------------- --------------- 
    Total costs and expenses                        156,139         155,715 
                                            --------------- --------------- 
Operating loss                                     (156,139)       (155,715)
Other income:                                                               
  Interest income                                       654           1,832 
                                            --------------- --------------- 
Loss before provision for income taxes             (155,485)       (153,883)
Provision for income taxes                                -               - 
                                            --------------- --------------- 
    Net loss                                $      (155,485)$      (153,883)
                                            =============== =============== 
Basic and diluted (loss) per weighted                                       
 average share of common stock outstanding  $         (0.01)$         (0.01)
                                            =============== =============== 
Weighted average shares of common stock                                     
 outstanding - basic and diluted                 13,144,040      13,144,040 
                                            =============== =============== 
                                                                            
                                                                            

Contact:
David Blitz
(212) 575-7800



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES